Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose is a Product of the Generic Fluticasone Propionate

What Is Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose Indications and Uses?

Adult : Fluair Inhaler is indicated in the prophylaxis and maintenance of mild, moderate and severe asthma. Fluair has a marked anti-inflammatory effect in the lungs. It reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator ... Read more Adult : Fluair Inhaler is indicated in the prophylaxis and maintenance of mild, moderate and severe asthma. Fluair has a marked anti-inflammatory effect in the lungs. It reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. Children : Any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Pharmacology (Source, Chemical and Physical Composition) Of Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose

Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose (Fluticasone Propionate) inhaler is a pressurized metered dose inhaler. It is intended for oral inhalation only. It contains Fluticasone Propionate BP as an active ingredient. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systemic effect of usual dose.

Drug Interactions of Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose

Under normal circumstances, due to low plasma concentrations of Fluair are achieved after inhaled dosing, clinically significant drug interactions mediated by Fluair are unlikely. Care should be taken when co-administering known strong cytochrome P450 3A4 inhibitors like ritonavir, ketoconazole and erythromycin.

Side Effects of Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose

Infections and infestations : Very common: Candidiasis of mouth and throat. Rare: Oesophageal candidiasis. Immune system disorders : Uncommon: Cutaneous hypersensitivity reactions. Very rare: Angioedema (mainly facial and oropharyngeal oedema), respiratory symptoms (dyspnoea and/or bronchospasm) and anaphylactic reactions. Endocrine disorders : Very rare: Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation, decreased bone mineral density, cataract and glaucoma. Metabolism and nutrition disorders : Very rare: Hyperglycaemia Psychiatric disorders : Very rare: Anxiety, sleep disorders and behavioural changes, including hyperactivity and irritability (predominantly in children). Respiratory, thoracic and mediastinal disorders : Common: Hoarseness. Very rare: Paradoxical bronchospasm. Skin and subcutaneous tissue disorders : Common: Contusions

Precautions And Warnings for Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose

Increasing use of short-acting inhaled B2-agonists to control asthma symptoms indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed. Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to increasing corticosteroid dosage. In patients considered at risk, daily peak flow monitoring may be instituted. Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral corticosteroids. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroid is regularly monitored. It is important, therefore, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained. Treatment with Fluair Inhaler should not be stopped abruptly. As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.

Use During Pregnancy and Lactation

Fertility : There are no data on human fertility. Animal studies indicate no effects of Fluair Metered-Dose Inhaler (MDI) Inhaler 125 mcg/metered dose (Fluticasone Propionate) on male or female fertility. Pregnancy : There are limited data in pregnant women. Administration of Fluticasone Propionate inhaler during pregnancy should only be considered if the expected benefit on the mother is greater than any possible risk to the foetus. Results from the retrospective epidemiological study did not find any increased risk of major congenital malformations (MCMs) following exposure to fluticasone propionate when compared to other inhaled corticosteroids, during the first trimester of pregnancy. Lactation : The excretion of fluticasone propionate into human breast milk has not been investigated. When measurable plasma levels were obtained in lactating laboratory rats following subcutaneous administration there was evidence of fluticasone propionate in the breast milk. However, plasma levels in patients following inhaled application of fluticasone propionate at recommended doses are likely to be low. Administration during lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the child.

Therapeutic Class

Fluocinolone & Combined Preparations, Respiratory corticosteroids

Storage Conditions of It

Pressurized canister, do not puncture, break or incinerate even when apparently empty. Avoid storage of direct sunlight and heat. Store below 30°C. Keep away from eyes. Keep away from children. Thanks for using MedEx! How would you rate your experience so far?